Epidemiological evidence supports that a higher leptin level was associated with a higher risk of recurrence in all breast cancer patients [14], and a lower adiponectin level was associated with a higher risk of recurrence in hormone receptor-negative breast cancer patients [15]. This evidence concerns the gene LEP and breast carcinoma.